Table 1 Overall demographics and exposures during international travel, number (%) of subjects (N = 58)
From: Antimicrobial resistance acquisition after international travel in U.S. travelers
Male gender | 24 (41) |
Age, median (minimum-maximum) | 64 (15–82) |
Regiona | |
 Mexico, Caribbean, & Central America | 18 (31) |
 Asia | 17 (29) |
 Africa | 16 (28) |
 Europe | 5 (9) |
 South America | 2 (3) |
 North America | 2 (3) |
Purpose of travela | |
 Vacation | 43 (74) |
 Visiting friends and relatives | 10 (17) |
 Other (missionary/volunteer) | 5 (9) |
 Deployment and military duty | 4 (7) |
 School | 1 (2) |
Duration of travel, median (minimum-maximum) | 12 days (6–105) |
Living conditionsa | |
 Hotel | 36 (62) |
 Friends and relatives | 13 (22) |
 Group livingb | 10 (17) |
 Boat/cruise | 7 (12) |
Local water ingestion during travel | 27 (47) |
Water exposures during travel | 20 (34) |
Antimicrobial exposure since enrollment | 23 (40) |
 Malaria chemoprophylaxis | 22 (38) |
  Atovaquone/Proguanil | 17 (29) |
  Doxycycline | 3 (5) |
  Chloroquine | 2 (3) |
 Antibiotics for traveler’s diarrhea since enrollment | 3 (5) |
  Ciprofloxacin | 2 (3) |
  Erythromycin | 1 (2) |
 Systemic antibiotics for other indications since enrollment | 3 (5) |
  Azithromycin | 1 (2) |
  Cephalexin | 1 (2) |
  Unknown antibiotic | 1 (2) |
Illness since enrollment | 13 (22) |
Duration of illness, median (minimum-maximum) | 4 days (1–27) |